News

Oryn therapeutics secures $3,000,000 of angel investment

By | Investment, News | No Comments

Mark Armenante, Founder and Board Member of Vlocity invests $1.5M in Oryn Therapeutics. Young Sohn, Founder and Board Member of Vlocity invests $1.5M in Oryn Therapeutics. This funding, along with the first ever Direct to Phase II SBIR award of $1.5M from The National Institute of Health will propel Oryn Therapeutics into Phase 1 clinical trials of the company’s novel rheumatoid arthritis drug.